In enzalutamide-treated prostate cancer cells, GR induces the expression of cAMP pathway-associated genes, leading to the nuclear accumulation of the cAMP-dependent protein kinase A catalytic subunit (PKA-c) (109). The gene discussed is NR3C1; the disease is prostate cancer.